5 FTSE stocks Fools think will lead the next bull market charge

Savvy Fools will know the time to be buying the best FTSE stocks isn’t when a new bull market is declared, but rather when the momentum isn’t obvious.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Silhouette of a bull standing on top of a landscape with the sun setting behind it

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Will these FTSE-listed stocks be among the biggest winners during the next upturn? These five Fools are confident!

AstraZeneca

What it does: AstraZeneca is a global biopharmaceutical company specialising in oncology, rare diseases, cardiovascular, and other areas.

Created with Highcharts 11.4.3AstraZeneca Plc PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

By Ben McPoland. AstraZeneca (LSE: AZN) is the largest company on the London Stock Exchange with a massive £191bn market cap. Whenever a new bull market gets going, I reckon the pharma firm’s size could help drive a fair bit of it.

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

The company is aiming to grow its revenue to $80bn between now and 2030. That would represent 75% growth, which would be impressive for an already giant business. It’s also investing in “disruptive innovation that will shape the future of medicine and drive long-term growth”.

As part of this, it recently acquired biotech Fusion Pharmaceuticals for up to $2.4bn, as well as Gracell Biotechnologies, a pioneer in CAR-T cell therapies. It’s also licensed an experimental pill from China’s Eccogene to try and break into the booming anti-obesity drug market.

Investors tend to get more bullish about innovative growth stories like this during bull markets.

Having said that, litigation is an ever-present risk in the industry, as are patent expirations, regulatory changes, and inevitable clinical trial disappointments. Still, I reckon AstraZeneca has what it takes to continue outperforming the UK market over time.  

Ben McPoland owns shares in AstraZeneca.

Burberry

What is does: Burberry is a British luxury brand with 229 retail stores across the globe.

Created with Highcharts 11.4.3Burberry Group Plc PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

By Andrew Mackie. One sector I fully expect to be at the forefront of outsized gains in the next bull market, is luxury retail. But for now, the industry is very much being buffeted from multiple angles. Burberry (LSE:BRBY) has been by far its worst performer. Its share price has collapsed by over 70% in just 15 months.

Its strategy of positioning itself as the Modern British Luxury brand has not delivered. Despite stating in its recent trading update that its strategy won’t change, I fully expect that the new CEO will quickly depart from decisions made by his predecessor.

The extent of its share price decline has taken me by surprise. But a company that has been around for as long as Burberry has, is not always going to get everything right.

The luxury market customer base continues to expand across generations and geographies. I fully expect it to provide growth and durability well into the future. I view its share price weakness as a wonderful opportunity. Indeed, the more it falls, the more shares I intend to buy.

Andrew Mackie owns shares in Burberry.

ITV

What it does: ITV is a television network owner and TV content creator

Created with Highcharts 11.4.3ITV PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

By Alan Oscroft. Investors have been pivoting away from big tech stocks, inflation is falling, and central banks are looking likelier to cut interest rates by the day.

To me, that says one thing. Investors should, with a bit of luck, come flocking back to some of the stocks they’ve shunned in the past few years. And I think ITV (LSE: ITV) might be one of them.

The ITV share price has been picking up this year, but it’s still way down since before the 2020 crash. And I just don’t think its valuation reflects its potential.

Competition has to be the biggest risk, and I fear that investor caution could weigh on the share price for a while. And priced at 14 times earnings, the shares don’t look super cheap.

But that could drop to under 10 on 2026 forecasts. And strongly rising cash flow should keep the dividend growing, from the 6% on the cards for 2024.

Alan Oscroft has no position in ITV.

Oxford Biomedica

What it does: A gene and cell therapy company specialising in the development of gene-based medicines. 

Created with Highcharts 11.4.3OXB PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

By Mark David Hartley. Oxford Biomedica (LSE: OXB) is a world-class pioneer in cell and gene therapy, providing services to the pharmaceutical and biotechnology industries. It specialises in developing therapies and treatments for chronic and deadly viruses like HIV.

Despite its groundbreaking developments, it’s not yet profitable. Its FY 2023 results revealed a loss of £1.63 per share, with a net loss of £157m and revenue down 36%. Like many young tech companies, it’s been spending a lot on R&D, resulting in losses. Whether that gamble pays off remains to be seen.

While the share price is down 22% over 12 months, it’s improved lately, rising 51% in Q2 this year. 

Based on future cash flow estimates, some analysts consider it undervalued by 70% and believe the company will become profitable in 2026. With an increasing demand for biomedical advancements, I agree and think it’ll take off in the next few years. 

Mark Hartley owns shares in Oxford Biomedica

Scottish Mortgage Investment Trust 

What it does: Scottish Mortgage is a Baillie Gifford fund that aims to “own the world’s most exceptional public and private growth companies”.

[fool_chart_ticker =LSE:SMT]

By Charlie Keough. One stock I see leading the next bull market charge is Scottish Mortgage Investment Trust (LSE: SMT). 

It owns some of the most exciting growth companies in the world, such as Elon Musk’s SpaceX. These companies suffer in high interest rate environments, so the trust has struggled over the last few years. 

But with cuts just around the corner, investor sentiment should turn more bullish on these sorts of companies. Falling rates are ideal for the disruptive businesses Scottish Mortgage owns because it means lower borrowing costs. 

The risk with investing in the trust is that its share price can be volatile, giving its large weighting to growth stocks. What’s more, around a quarter of its holdings are private companies. Pinpointing the value of these businesses can be difficult. 

However, we saw just what the stock could do when it rose by over 100% during 2020. And it’s 41.9% off the all-time high it hit in 2021. As such, it’s currently trading at a 9% discount to its net asset value. 

Of course, past performance is no indication of future returns. But I’m still optimistic, despite climbing 10.6% year to date, we could see Scottish Mortgage rise further in the months and years ahead. 

Charlie Keough owns shares in Scottish Mortgage. 

But here’s another bargain investment that looks absurdly dirt-cheap:

Like buying £1 for 31p

This seems ridiculous, but we almost never see shares looking this cheap. Yet this Share Advisor pick has a price/book ratio of 0.31. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 31p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 10%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

The Motley Fool UK has recommended AstraZeneca Plc, Burberry Group Plc, and ITV. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

My top 2 stock market predictions for 2025

This writer didn’t receive a crystal ball for Christmas, but he still has a couple of stock market predictions for…

Read more »

Investing Articles

3 companies that could emulate Nvidia stock’s success in 2025

Nvidia stock has generated market topping growth over the past two years. But investors need to be asking themselves, who…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

Here’s my plan for maximising the returns from my Stocks and Shares ISA in 2025

After a good 2024, Stephen Wright has two key ideas he wants to implement in his Stocks and Shares ISA…

Read more »

Investing Articles

3 key FTSE 100 stock updates to watch for in January

My 2025 investing focus is on key FTSE 100 stocks in key sectors, and we won't have very long to…

Read more »

Investing Articles

Why the Diageo share price fell 10% in 2024

The Diageo share price fell 10% last year. But Stephen Wright thinks the stock market's being too pessimistic about a…

Read more »

White female supervisor working at an oil rig
Investing Articles

Why the BP share price fell 16% in 2024

Oil prices have been falling since April causing BP shares to do the same. But Stephen Wright thinks there’s much…

Read more »

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

Could these UK shares help investors beat the FTSE 100 and S&P 500?

I reckon these brilliant blue-chip UK shares might just beat both the FTSE 100 and S&P 500 indexes over the…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

Best US stocks to consider buying in 2025

We asked our freelance writers to reveal the top US stocks they think investors should think about buying in 2025.

Read more »